

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery

Interventional procedures guidance

Published: 26 July 2006

[nice.org.uk/guidance/ipg184](https://www.nice.org.uk/guidance/ipg184)

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

1 Guidance

- 1.1 Current evidence on the safety and efficacy of high-intensity focused ultrasound (HIFU) for atrial fibrillation in association with other cardiac surgery

is insufficient for this procedure to be used without special arrangements for consent and for audit or research.

- 1.2 Clinicians wishing to undertake HIFU for atrial fibrillation in association with other cardiac surgery should take the following actions.
- Inform the clinical governance leads in their Trusts.
 - Ensure that patients understand the uncertainty about the procedure's safety and efficacy and provide them with clear written information. In addition, use of the Institute's [information for patients](#) is recommended.
 - Audit and review clinical outcomes of all patients undergoing HIFU for atrial fibrillation in association with other cardiac surgery.
- 1.3 Patient selection and follow-up should be carried out by a multidisciplinary team. Cardiac surgeons undertaking this procedure should have specific training in the use of high-intensity focused ultrasound equipment.
- 1.4 Publication of safety and efficacy outcomes will be useful. The Institute may review the procedure upon publication of further evidence.

2 The procedure

2.1 *Indications*

- 2.1.1 Atrial fibrillation is the irregular and rapid beating of the upper two chambers of the heart (the atria). It can be classified as paroxysmal, persistent or permanent. Patients with atrial fibrillation may be asymptomatic or may have symptoms such as palpitations, dizziness, breathlessness and fatigue. They have an increased risk of stroke as a result of blood clots forming in the left atrium and then embolising to the brain.
- 2.1.2 Atrial fibrillation usually occurs in the absence of structural heart disease.
- 2.1.3 Conservative treatments are medication to control the heart rhythm and rate, electrical cardioversion and anticoagulation to prevent the formation of blood clots. Surgery for atrial fibrillation is usually performed at the same time as open heart surgery for another indication, such as the correction of mitral-valve

disease. The conventional surgical approach, including the maze procedure, involves making multiple, strategically placed incisions in both atria to isolate and stop the abnormal electrical impulses. Alternative non-surgical methods of creating lesions in the atria by ablation have been developed using energy sources such as radiofrequency, microwave, cryotherapy, laser and ultrasound.

2.2 *Outline of the procedure*

2.2.1 HIFU for atrial fibrillation is typically carried out in patients undergoing concomitant open heart surgery (often for mitral-valve replacement or repair). An ultrasound device is placed outside the left atrium of the beating heart and delivers focused ultrasound energy across the wall of the heart. Absorption of the ultrasound energy creates a rise in temperature, which destroys the cardiac tissue within the focal area and disrupts the transmission of the abnormal electrical impulses.

2.3 *Efficacy*

2.3.1 Efficacy is based on the results of one case series of 103 patients, in which 85% (80/94) of patients were free from atrial fibrillation at 6 months' follow-up, including 80% of patients who had permanent atrial fibrillation and 100% of patients who had intermittent (paroxysmal or persistent) atrial fibrillation. For more details, refer to the 'Sources of evidence' section.

2.3.2 The Specialist Advisers stated that the key efficacy outcomes should include normalisation of sinus rhythm, persistence or recurrence of atrial fibrillation, atrial transport function and quality of life.

2.4 *Safety*

2.4.1 This procedure is performed during open heart surgery; therefore it is difficult to differentiate the complications that relate specifically to HIFU ablation.

2.4.2 Evidence of safety was based on the same case series of 103 patients. Early (up to 30 days after the operation) and late (more than 30 days after the operation) complications were reported in the case series, but none were considered to be related to the device or the procedure. Early complications included: bleeding that required surgical exploration in 6% (6/103) of patients; complete heart

block in 4% (4/103) and sinus node dysfunction in 1% (1/103), both of which required implantation of permanent pacemakers; stroke in 3% (3/103) and serious deep wound infection in 1% (1/103). Late complications included sinus node dysfunction requiring implantation of a permanent pacemaker in 3% (3/103) of patients, multiple organ failure in 1% (1/103), delayed cardiac tamponade in 1% (1/103) and transient ischaemic attack in 1% (1/103).

2.4.3 Mortality at 6 months' follow-up was 6% (6/103) in this case series: 4% (4/103) early deaths and 2% (2/103) late non-cardiac deaths. For more details, refer to the 'Sources of evidence' section.

2.4.4 The Specialist Advisers noted that theoretical adverse events include excess myocardial damage (resulting in lack of atrial transportation), damage to adjacent structures (particularly the pulmonary veins, oesophagus and phrenic nerve) and an increase in surgical risk resulting from prolonged bypass time (if bypass is required).

2.5 *Other comments*

2.5.1 It was noted that technique and HIFU settings used for this procedure varied. It was also noted that it may be difficult to determine when full-thickness ablation has been achieved.

3 Further information

3.1 The Institute has issued guidance on [radiofrequency ablation](#), [microwave ablation](#) and [cryoablation](#) for atrial fibrillation in association with other cardiac surgery. It has also issued guidance on [percutaneous radiofrequency ablation for atrial fibrillation](#).

3.2 The Institute has issued a clinical guideline on [atrial fibrillation](#).

Andrew Dillon
Chief Executive
July 2006

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.

'Interventional procedure overview of high-intensity focused ultrasound ablation for atrial fibrillation as an associated procedure with other cardiac surgery', October 2005.

Information for patients

NICE has produced [information on this procedure for patients and carers](#). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

4 Changes since publication

NICE has reviewed this guidance and is reassessing the procedure. New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the recommendations in this guidance.

The Interventional Procedures Advisory Committee (IPAC) will consider this procedure review and NICE will issue an Interventional Procedures Consultation Document about its safety and efficacy for 4 weeks public consultation. IPAC will then review the consultation document in the light of comments received and produce a Final Interventional Procedures Document, which will be considered by NICE before guidance is issued to the NHS in England, Wales, Scotland and Northern Ireland.

If you wish to be updated to any developments with this procedure, you can express an interest via our [website](#).

19 January 2012: minor maintenance.

5 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people

using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE [interventional procedure guidance](#) process.

We have produced a [summary of this guidance for patients and carers](#). Information about the evidence it is based on is also [available](#).

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2006. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.